Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Summary, in English

To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers.

• Author: Kelly-Anne Phillips; Roger L Milne; Matti A Rookus; Mary B Daly; Antonis C Antoniou; Susan Peock; Debra Frost; Douglas F Easton; Steve Ellis; Michael L Friedlander; Saundra S Buys; Nadine Andrieu; Catherine Noguès; Dominique Stoppa-Lyonnet; Valérie Bonadona; Pascal Pujol; Sue Anne McLachlan; Esther M John; Maartje J Hooning; Caroline Seynaeve; Rob A E M Tollenaar; David E Goldgar; Mary Beth Terry; Trinidad Caldes; Prue C Weideman; Irene L Andrulis; Christian F Singer; Kate Birch; Jacques Simard; Melissa C Southey; Håkan Olsson; Anna Jakubowska; Edith Olah; Anne-Marie Gerdes; Lenka Foretova; John L Hopper
• Department/s: Breastcancer-genetics; EpiHealth: Epidemiology for Health; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2013
• Language: English
• Pages: 3091-3091
• Publication/Series: Journal of Clinical Oncology
• Volume: 31
• Issue: 25
• Links: http://www.ncbi.nlm.nih.gov/pubmed/23918944?dopt=Abstract; http://dx.doi.org/10.1200/JCO.2012.47.8313
• Document type: Journal article
• Publisher: American Society of Clinical Oncology
• Topic: Cancer and Oncology
• Status: Published
• ISBN/ISSN/Other: ISSN: 1527-7755